Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06719141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 24 words
    • Study sites revised (116)
  2. Enrollment increased: 292 → 367 participants
    • Study sites revised (116)
    v21
  3. Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment target: estimated 320 to confirmed 292
    • Study sites: 114 to 116
    v20
  4. Trial sites expanded: 110 → 114 locationsv19
  5. Study sites: 109 to 110v18
  6. Trial sites expanded: 106 → 109 locationsv17
  7. Study sites: 101 to 106v16
  8. Study sites: 95 to 101
    • Eligibility criteria revised
    v15
  9. Re-verified, no change to tracked fieldsv14
  10. Study sites: 80 to 95v13
  11. Study sites: 72 to 80v12
  12. Study sites: 57 to 72v11
  13. Study sites: 40 to 57v10
  14. Study sites: 22 to 40v9
  15. Study sites: 99 to 22
    • Primary completion date: Oct 2026 to Oct 31, 2026
    • Study completion date: Nov 2026 to Nov 30, 2026
    v8
  16. Site details revised at 6 of 99 sitesv7
  17. Site details revised at 1 of 99 sitesv6
  18. Site details revised at 2 of 99 sitesv5
  19. Study sites revised (99)v4
  20. Study sites: 33 to 99v3
  21. Study sites: 7 to 33v2
  22. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Trial Details
NCT Number NCT06719141
Lead Sponsor Longboard Pharmaceuticals
Conditions
(from sponsor)		 Developmental and Epileptic Encephalopathy
Related terms Epilepsy, Lennox Gastaut Syndrome, Neurodevelopmental Disorders, Seizures
Enrollment 367 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov